Cleveland BioLabs Company Profile (NASDAQ:CBLI)

About Cleveland BioLabs (NASDAQ:CBLI)

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology & Medical Research
Sub-Industry: N/A
Symbol: NASDAQ:CBLI
CUSIP: N/A
Web: www.cbiolabs.com

Capitalization:

Market Cap: $34.29 million
Outstanding Shares: 11,279,000

Average Prices:

50 Day Moving Avg: $2.78
200 Day Moving Avg: $2.82
52 Week Range: $1.22 - $5.55

P/E:

Trailing P/E Ratio: N/A
P/E Growth: 0.00

Sales & Book Value:

Annual Revenue: $2.91 million
Price / Sales: 12.60
Book Value: $0.41 per share
Price / Book: 7.93

Profitability:

EBIDTA: ($5,710,000.00)
Net Margins: -253.09%
Return on Equity: -61.18%
Return on Assets: -49.90%

Debt:

Current Ratio: 5.18%
Quick Ratio: 5.18%

Misc:

Average Volume: 63,584 shs.
Beta: 0.2
Short Ratio: 2.13

Frequently Asked Questions for Cleveland BioLabs (NASDAQ:CBLI)

What is Cleveland BioLabs' stock symbol?

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

How were Cleveland BioLabs' earnings last quarter?

Cleveland BioLabs, Inc. (NASDAQ:CBLI) posted its earnings results on Monday, August, 14th. The company reported ($0.50) EPS for the quarter. The company earned $0.21 million during the quarter. Cleveland BioLabs had a negative return on equity of 61.18% and a negative net margin of 253.09%. View Cleveland BioLabs' Earnings History.

Who are some of Cleveland BioLabs' key competitors?

Some companies that are related to Cleveland BioLabs include NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Navidea Biopharmaceuticals (NAVB), Galectin Therapeutics (GALT), Infinity Pharmaceuticals (INFI), ReNeuron Group Plc (RENE), Fibrocell Science (FCSC), OvaScience (OVAS), Sunesis Pharmaceuticals (SNSS), Abzena PLC (ABZA), Aptose Biosciences (APTO), Prima BioMed Ltd (PBMD), Caladrius Biosciences (CLBS), Bio-Path Holdings (BPTH), AEterna Zentaris (AEZS), Scancell Holdings Plc (SCLP), Oncobiologics (ONS) and Senomyx (SNMX).

Who are Cleveland BioLabs' key executives?

Cleveland BioLabs' management team includes the folowing people:

Langdon L. Miller M.D., President
Yakov N. Kogan Ph.D., Chief Executive Officer, Principal Financial Officer
Andrei V. Gudkov Ph.D., Chief Scientific Officer
Alexander Andryushechkin, Independent Director
Anna Evdokimova, Independent Director
Alexey Nechaev, Independent Director
Ivan Persiyanov, Independent Director
Randy S. Saluck J.D., Independent Director

Who owns Cleveland BioLabs stock?

Cleveland BioLabs' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.51%) and Virtu KCG Holdings LLC (0.46%). View Institutional Ownership Trends for Cleveland BioLabs.

Who bought Cleveland BioLabs stock? Who is buying Cleveland BioLabs stock?

Cleveland BioLabs' stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Virtu KCG Holdings LLC. View Insider Buying and Selling for Cleveland BioLabs.

How do I buy Cleveland BioLabs stock?

Shares of Cleveland BioLabs can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cleveland BioLabs' stock price today?

One share of Cleveland BioLabs stock can currently be purchased for approximately $3.25.

MarketBeat Community Rating for Cleveland BioLabs (NASDAQ CBLI)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		41 (Vote Outperform)
Underperform Votes:		28 (Vote Underperform)
Total Votes:		69

MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for Cleveland BioLabs (NASDAQ:CBLI) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	No ratings tracked in the last 12 months.
Consensus Rating:	N/A (Score: NaN)
Consensus Price Target:	N/A

Analysts' Ratings History for Cleveland BioLabs (NASDAQ:CBLI)

Show:

No equities research coverage for this company has been tracked by MarketBeat.com

Earnings History for Cleveland BioLabs (NASDAQ:CBLI)

Earnings by Quarter for Cleveland BioLabs (NASDAQ:CBLI)

Earnings History by Quarter for Cleveland BioLabs (NASDAQ CBLI)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/14/2017	Q2 2017		($0.50)		$0.21 million	View	N/A
5/15/2017	Q1 2017		($0.15)		$0.58 million	View	N/A
2/22/2017	Q4 2016		($0.11)		$0.99 million	View	N/A
8/15/2016	Q2		($0.17)		$0.58 million	View	N/A
5/16/2016	Q116		($0.06)		$0.81 million	View	N/A
11/5/2015	Q315		$0.31	$415.00 million	$0.50 million	View	N/A
8/12/2015	Q215		($0.72)	$562.10 million	$329.90 million	View	Listen
5/6/2015	Q115		($1.14)	$1.33 million	$0.61 million	View	N/A
2/24/2015	Q114		($1.02)	$3.87 million	$1.39 million	View	N/A
3/11/2014	Q413	($0.12)	($0.01)	$1.74 million	$3.87 million	View	N/A
11/6/2013	Q313	($0.14)	($0.09)	$1.61 million	$1.60 million	View	N/A
8/13/2013	Q2 2013	($0.16)	($0.07)	$1.48 million	$1.60 million	View	N/A
5/9/2013	Q1 2013	($0.17)	($0.22)	$1.73 million	$1.37 million	View	N/A
11/8/2012	Q312	($0.02)	($0.30)	$23.87 million		View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Cleveland BioLabs (NASDAQ:CBLI)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Cleveland BioLabs (NASDAQ:CBLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for Cleveland BioLabs (NASDAQ:CBLI)

Insider Ownership Percentage: 2.44%
Institutional Ownership Percentage: 4.58%

Insider Trades by Quarter for Cleveland BioLabs (NASDAQ:CBLI)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
2/25/2015	Randy S Saluck	Director	Buy	1,891	$3.42	$6,467.22
5/21/2013	Paul E Dicorleto	Director	Buy	6,210	$1.61	$9,998.10
5/17/2013	Randy S Saluck	Director	Buy	3,500	$1.60	$5,600.00
3/15/2013	James Antal	Director	Buy	3,700	$1.56	$5,772.00
9/21/2012	James Antal	Director	Buy	2,316	$2.60	$6,021.60

(Data available from 1/1/2013 forward)

Headline Trends for Cleveland BioLabs (NASDAQ:CBLI) Latest Headlines for Cleveland BioLabs (NASDAQ:CBLI)

Source:

Date	Headline
	ETFs with exposure to Cleveland BioLabs, Inc. : September 19, 2017 finance.yahoo.com - September 19 at 10:01 PM
	Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 finance.yahoo.com - September 18 at 5:17 PM
	Contrasting Cleveland BioLabs (CBLI) and Asterias Biotherapeutics (AST) www.americanbankingnews.com - September 17 at 2:31 AM
	What You Must Know About Cleveland BioLabs Inc’s (CBLI) Risks finance.yahoo.com - September 11 at 5:34 PM
	Cleveland BioLabs, Inc. (CBLI) Posts Earnings Results www.americanbankingnews.com - August 15 at 9:41 AM
	Cleveland Biolabs Countermeasure for Acute Radiation Syndrome, Pipeline Review, and Market Potential finance.yahoo.com - August 11 at 5:26 PM
	ETFs with exposure to Cleveland BioLabs, Inc. : August 4, 2017 finance.yahoo.com - August 4 at 10:18 PM
	ETFs with exposure to Cleveland BioLabs, Inc. : July 12, 2017 finance.yahoo.com - July 12 at 5:35 PM
	ValuEngine Downgrades Cleveland BioLabs, Inc. (CBLI) to Sell www.americanbankingnews.com - June 29 at 11:08 PM
	ETFs with exposure to Cleveland BioLabs, Inc. : June 26, 2017 finance.yahoo.com - June 26 at 4:51 PM
	ETFs with exposure to Cleveland BioLabs, Inc. : June 16, 2017 finance.yahoo.com - June 16 at 4:56 PM
	Short Interest in Cleveland BioLabs, Inc. (CBLI) Decreases By 50.5% www.americanbankingnews.com - June 13 at 7:04 AM
	ETFs with exposure to Cleveland BioLabs, Inc. : June 5, 2017 finance.yahoo.com - June 5 at 4:07 PM
	Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 finance.yahoo.com - June 2 at 5:39 PM
	Short Interest in Cleveland BioLabs, Inc. (CBLI) Drops By 30.7% www.americanbankingnews.com - May 29 at 7:14 AM
	Cleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress feeds.benzinga.com - May 15 at 8:01 AM
	Cleveland BioLabs (CBLI) Earning Critical Media Coverage, Report Shows www.americanbankingnews.com - April 21 at 7:49 AM
	Governments Looking at Cleveland Biolabs Radiation Countermeasure finance.yahoo.com - April 20 at 11:08 AM
	Gainers & Losers Of Apr.19: SNGX, IMGN, CBLI, SSH, AKTX... www.finanznachrichten.de - April 19 at 11:03 PM
	ETFs with exposure to Cleveland BioLabs, Inc. : April 19, 2017 finance.yahoo.com - April 19 at 6:02 PM
	Cleveland BioLabs, Inc. (CBLI) Stock Tacks On Another 40%-Plus investorplace.com - April 19 at 3:33 PM
	Cleveland Biolabs (CBLI) to Begin In Vivo Bio-Comparability Study Following FDA Review www.streetinsider.com - April 19 at 1:01 PM
	Cleveland BioLabs (CBLI) Earning Somewhat Positive Media Coverage, Analysis Finds www.americanbankingnews.com - April 18 at 1:38 PM
	Cleveland BioLabs Announces European Medicines Agency Positive Opinion Regarding the Entolimod Pediatric Investigation Plan finance.yahoo.com - April 17 at 12:17 PM
	Cleveland BioLabs Announces Commencement of In Vivo Biocomparability Study finance.yahoo.com - April 17 at 12:17 PM
	ETFs with exposure to Cleveland BioLabs, Inc. : April 7, 2017 finance.yahoo.com - April 7 at 9:11 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh biz.yahoo.com - February 22 at 9:21 PM
	Cleveland BioLabs Reports 2016 Financial Results and Development Progress finance.yahoo.com - February 22 at 4:20 PM
	CLEVELAND BIOLABS INC Financials finance.yahoo.com - November 20 at 8:11 AM
	Cleveland Biolabs (CBLI) Announces $1.1M JWMRP Contract Modification with U.S. DoD www.streetinsider.com - October 12 at 8:37 AM
	BRIEF-Cleveland BioLabs announces a $1.1 mln cost realignment with Department of Defense www.reuters.com - October 11 at 4:13 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers biz.yahoo.com - July 22 at 4:22 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta biz.yahoo.com - July 21 at 6:05 AM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand biz.yahoo.com - July 12 at 4:25 PM
	22nd Century to begin cannabis research at new medical campus labs www.bizjournals.com - May 12 at 2:40 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit biz.yahoo.com - May 6 at 5:55 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders biz.yahoo.com - April 15 at 3:05 PM
	GLPG Awaits SAPHIRA Data, VTAE Vaults, CBLI Hits A Snag www.rttnews.com - March 17 at 2:04 AM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Other Events biz.yahoo.com - March 16 at 2:50 PM
	Cleveland BioLabs Provides Update on Pre-EUA Review of Entolimod as Radiation Countermeasure finance.yahoo.com - March 16 at 2:00 PM
	Hottest Services Stocks Now – CAI NEWT INST MOBL investorplace.com - March 8 at 11:42 AM
	CLEVELAND BIOLABS INC Files SEC form 10-K, Annual Report biz.yahoo.com - February 23 at 5:04 PM
	CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition biz.yahoo.com - February 22 at 10:35 AM
	Cleveland BioLabs Reports 2015 Financial Results and Development Progress finance.yahoo.com - February 22 at 7:30 AM
	Cleveland BioLabs, Inc. (CBLI) biz.yahoo.com - February 18 at 6:31 PM
	Hottest Services Stocks Now – ADUS SREV EBIX CBLI investorplace.com - February 9 at 10:47 AM
	Cleveland Biolabs (CBLI) Says Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis www.streetinsider.com - February 9 at 10:47 AM
	Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute finance.yahoo.com - February 9 at 7:30 AM
	Cleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation finance.yahoo.com - February 2 at 8:00 AM
	Cleveland BioLabs Gets Orphan Status for Entolimod in EU finance.yahoo.com - January 22 at 3:25 PM